These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV. Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD008270. PubMed ID: 23740608 [TBL] [Abstract][Full Text] [Related]
3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Van Vaerenbergh K Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503 [TBL] [Abstract][Full Text] [Related]
4. Abacavir: a review of its clinical potential in patients with HIV infection. Hervey PS; Perry CM Drugs; 2000 Aug; 60(2):447-79. PubMed ID: 10983741 [TBL] [Abstract][Full Text] [Related]
6. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients. Manfredi R; Calza L AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748 [TBL] [Abstract][Full Text] [Related]
7. Delavirdine: a review of its use in HIV infection. Scott LJ; Perry CM Drugs; 2000 Dec; 60(6):1411-44. PubMed ID: 11152019 [TBL] [Abstract][Full Text] [Related]
8. Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients. Cuzin L; Pugliese P; Bugnon F; Delpierre C; Cua E; Billaud E; Massip P; Raffi F; Dellamonica P HIV Med; 2005 Nov; 6(6):388-95. PubMed ID: 16268820 [TBL] [Abstract][Full Text] [Related]
9. Nucleoside and nucleotide reverse transcriptase inhibitors in children. Giaquinto C; Rampon O; Penazzato M; Fregonese F; De Rossi A; D'Elia R Clin Drug Investig; 2007; 27(8):509-31. PubMed ID: 17638393 [TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of antiretroviral combination therapy based on protease inhibitors or non-nucleoside analogue reverse transcriptase inhibitors: indirect comparison of controlled trials. Yazdanpanah Y; Sissoko D; Egger M; Mouton Y; Zwahlen M; Chêne G BMJ; 2004 Jan; 328(7434):249. PubMed ID: 14742351 [TBL] [Abstract][Full Text] [Related]
11. Higher virological effectiveness of NNRTI-based antiretroviral regimens containing nevirapine or efavirenz compared to a triple NRTI regimen as initial therapy in HIV-1-infected adults. Pérez-Elías MJ; Moreno A; Moreno S; López D; Antela A; Casado JL; Dronda F; Gutiérrez C; Quereda C; Navas E; Abraira V; Rodríguez MA HIV Clin Trials; 2005; 6(6):312-9. PubMed ID: 16452065 [TBL] [Abstract][Full Text] [Related]
12. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program. Jaspan HB; Berrisford AE; Boulle AM Pediatr Infect Dis J; 2008 Nov; 27(11):993-8. PubMed ID: 18818556 [TBL] [Abstract][Full Text] [Related]
14. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial. Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E; Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227 [TBL] [Abstract][Full Text] [Related]
15. Successful simplification of protease inhibitor-based HAART with triple nucleoside regimens in children vertically infected with HIV. Palma P; Romiti ML; Cancrini C; Pensieroso S; Montesano C; Santucci MB; Bernardi S; Martino AM; Rossi P; Castelli-Gattinara G AIDS; 2007 Nov; 21(18):2465-72. PubMed ID: 18025883 [TBL] [Abstract][Full Text] [Related]
16. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial. MacArthur RD; Novak RM; Peng G; Chen L; Xiang Y; Hullsiek KH; Kozal MJ; van den Berg-Wolf M; Henely C; Schmetter B; Dehlinger M; ; Lancet; 2006 Dec; 368(9553):2125-35. PubMed ID: 17174704 [TBL] [Abstract][Full Text] [Related]
17. Nucleoside reverse transcriptase inhibitor-reducing strategies in HIV treatment: assessing the evidence. Orkin C; Llibre JM; Gallien S; Antinori A; Behrens G; Carr A HIV Med; 2018 Jan; 19(1):18-32. PubMed ID: 28737291 [TBL] [Abstract][Full Text] [Related]
18. An introduction to nucleoside and nucleotide analogues. Squires KE Antivir Ther; 2001; 6 Suppl 3():1-14. PubMed ID: 11678469 [TBL] [Abstract][Full Text] [Related]
19. Assessing efficacy of different nucleos(t)ide backbones in NNRTI-containing regimens in the Swiss HIV Cohort Study. Yang WL; Kouyos RD; Scherrer AU; Böni J; Shah C; Yerly S; Klimkait T; Aubert V; Hirzel C; Battegay M; Cavassini M; Bernasconi E; Vernazza P; Held L; Ledergerber B; Günthard HF; ; J Antimicrob Chemother; 2015 Dec; 70(12):3323-31. PubMed ID: 26362944 [TBL] [Abstract][Full Text] [Related]
20. Zidovudine: a review of its use in the management of vertically-acquired pediatric HIV infection. Bhana N; Ormrod D; Perry CM; Figgitt DP Paediatr Drugs; 2002; 4(8):515-53. PubMed ID: 12126455 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]